Boehringer Ingelheim, a leading provider of animal health products for pets and livestock, announced plans to expand its facility in St. Joseph, Missouri. The 13,000 sq. ft. expansion will accommodate increased production of livestock animal vaccines sold in the U.S. and globally, and is expected to create 20 new jobs. The company currently employs more than 1,000 people in Missouri.
Boehringer Ingelheim’s expansion will add to its 700,000 sq. ft. campus in St. Joseph, which also includes a warehouse, research and development and other support functions, and is expected to be completed in 2019. Boehringer Ingelheim announced the news in conjunction with an expansion in its Athens, GA, facility.
“The vaccines manufactured today in Athens and St. Joseph make a major difference for both the pets and livestock animals of our customers. The company has pioneered many important advancements in vaccines, and we continue to focus on health and prevention as core principles of our Animal Health business,” said Veronique Kodjo, global head of industrial operations for Boehringer Ingelheim’s Animal Health business. “These significant investments in expansion and capacity ensure that we can continue to support our future business growth areas.”
The company’s St Joseph facilities are its largest animal health manufacturing operation globally, and the site recently celebrated the 100th anniversary of its presence in the community.
Missouri is home to dynamic animal health and plant science clusters. Statewide, pet food companies with their North American headquarters in Missouri generate almost $30 billion in revenue each year, and more than half of the world’s animal health industry is represented in the Kansas City region.
For more information on why Missouri could be a prime location to launch or grow your business, contact Steve Johnson, CEO of Missouri Partnership, at 314.725.2688 or via our contact form, with any questions you might have, and learn how Missouri Partnership can help with your business expansion needs.